Recombinant infusion therapies indicated for bleeding disorders

Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA.
Journal of infusion nursing: the official publication of the Infusion Nurses Society 01/2011; 34(1):29-35. DOI: 10.1097/NAN.0b013e31820219ff
Source: PubMed


Hemophilia is a genetic condition that causes prolonged bleeding in those affected after surgeries, dental procedures, and injuries. It has been treated with a variety of products in the modern era, with some of the treatments causing serious viral infections. The development of recombinant-factor products has led to longer life expectancy and better quality of life for those affected. The objectives of this article are to review the epidemiology and pathophysiology of hemophilia A and B and von Willebrand's disease and to outline the development of treatment products, along with the advantages and disadvantages of each product. Research on newer products is progressing at a rapid pace. The article will also discuss some of the newer products currently in development.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: OVERVIEW: Von Willebrand disease is the most common inherited bleeding disorder, with an estimated prevalence of up to 1.3% of the U.S. population, or 4 million Americans. It's caused by a deficiency of or defects in von Willebrand factor, a protein necessary for blood to clot. Many nurses and other health care providers, as well as patients, are unaware of the disorder, its symptoms, and its associated risks. Although the disorder occurs equally in males and females, it can be more troublesome in females. Heavy menses beginning at menarche is one of the most common presentations, but because the disorder is inherited and other family members may have similarly heavy menses, the assumption may be that this is normal. This article describes von Willebrand disease and its three types, explains how to recognize and investigate suggestive symptoms, and outlines management strategies.
    The American journal of nursing 05/2012; 112(6):38-44; quiz 46, 45. DOI:10.1097/01.NAJ.0000415122.54111.f4 · 1.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive procedures for patients with bleeding disorders require planning on the part of the health care team. The patient population affected involves those with hereditary bleeding disorders, such as von Willebrand disease or hemophilia; in addition, patients who use antithrombotic drugs must be considered and their care managed. The choice of treatment depends on a number of factors, including the procedure planned, the type and severity of the disorder, and the age and morbidity of the patient. The indications, dosing, and timing of presurgical and surgical interventions will be reviewed, as well as special considerations for vascular access devices.
    Journal of infusion nursing: the official publication of the Infusion Nurses Society 03/2014; 37(2):88-94. DOI:10.1097/NAN.0000000000000023